Novo Nordisk Investor Presentation - First Nine Months of 2016

Investor presentation First nine months of 2016 Slide 44 Solid US modern insulin market share US insulin market by segments Device penetration Modern Insulin penetration Novo Nordisk US modern insulin volume market shares Sanofi Eli Lilly tMU 140 CAGR volume¹: 2.1% CAGR value¹: 28.6% Penetration 100% 60% 120 50% 80% 100 Fast-acting 40% 60% 80 41% 38% Premix 30% 60 40% 20% 40 21% 20% 20 10% Long-acting 0 0% 0% Aug 2011 Aug 2016 Aug 2011 Aug 2016 1 CAGR for 5-year period Source: IMS Monthly MAT August, 2016 volume and value (DKK) figures changing diabetes Source: IMS Monthly MAT August, 2016 volume figures novo nordisk

View entire presentation